RhoVac seeks a partnership among larger oncology focused pharmaceutical companies, companies that have the capability and the financial strength to run a broad-based phase III program and that, after regulatory approval, are able to successfully launch the product globally.

We will consider both licensing and acquisition/divestment options after the phase IIB study results are at hand in 2021, and we could consider an option deal prior to that.

For questions about partnership, please contact:
Anders Månsson
RhoVac Group
Tel. +46 708 60 47 38

Event Calendar

September 10-12, 2019

Nordic Life Science Day, Malmo

September 25-26, 2019

Annual EU Biotech, Basel

September 27 - October 1, 2019

ESMO, Barcelona

October 1-2, 2019

French-Swedish LSD, Paris

November 11-13, 2019

BIO Europe, Hamburg